EP Patent

EP0320051B1 — Controlled release combination of carbidopa/levodopa

Assigned to Merck and Co Inc · Expires 1992-11-04 · 34y expired

What this patent protects

A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with…

USPTO Abstract

A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levodopa combinations presently employed.

Drugs covered by this patent

Patent Metadata

Patent number
EP0320051B1
Jurisdiction
EP
Classification
—
Expires
1992-11-04
Drug substance claim
No
Drug product claim
No
Assignee
Merck and Co Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.